Virios Therapeutics, Inc. announced that it expects top-line results from its Phase 2 Post-Acute Sequelae of COVID-19 (also known as PASC or Long-COVID) exploratory clinical trial to be available in June 2023. This study will assess the potential of the antiviral combination of valacyclovir and celecoxib to provide symptomatic improvements in patients suffering from Long-COVID when added to standard of care therapy. Outcomes being assessed in this study include fatigue, sleep, attention, pain, autonomic function, memory and anxiety.

Prevalence estimates suggest over 600 million people worldwide have been infected with COVID-19 (SARS-CoV-2). As many as 30% of COVID-19 patients will experience some degree of PASC symptoms. SARS-CoV-2 infection appears to be a potent trigger for reactivation of latent herpes virus infection. Neurocognitive impairment and fatigue have been linked to reactivation of the Epstein-Barr form of herpes virus.

This study is supported via an unrestricted investigational grant to the Bateman Horne Center, a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, post-viral syndromes including Long-COVID, and related comorbidities.